SPARK Norway Educational Forum: Repurposing
Repurposing of drugs can potentially bring medications with known safety profiles to new patient groups. What is the industry looking for when they consider to invest in a repurposing project? What is the regulatory framework in this area? How is IP handled?
The meeting is part of the SPARK Norway Educational Forum Series 3: Therapeutics and diagnostics – monthly open meetings organized by UiO:Life Science and SPARK Norway partners.
The questions above are among the questions that will be addressed in this seminar.
- Industrial perspective
Olav Flaten, Hunemo/AURA Biopharm
Olav has worked many years in international biotech and pharma industry, with longstanding executive experience from different countries. He is an experienced consultant in commercialization, partnering and business development for companies engaged in biotechnology, medical technology, pharmaceuticals and nutraceuticals.
- Regulatory framework
Jan Petter Akselsen, The Norwegian Medicines Agency
- IP considerations
Kirsten Stangebye and Eivind Roverud, Inven2
Kirsten and Eivind are responsible for Inven2's patent portfolio, including securing IP and advising on patentability and patent strategy in Inven2's commercialization projects. Kirsten has been IPR manager at Inven2 since 2007 (Birkeland Innovation 2007–2010). Eivind joined Inven2 in 2017, bringing experience from Yara International and Xellia Pharmaceuticals.